Arvaya Healthcare (BOM:524723) Research & Development: ₹0.00 Mil (TTM As of Mar. 2026)


BOM:524723 Arvaya Healthcare Ltd BOM:524723
34 GF Score
Price ₹67.11
GF Value ₹49.05
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Arvaya Healthcare Research & Development?

Arvaya Healthcare BOM:524723 34 Research & Development is ₹0.00 Mil as of Mar. 2026. GuruFocus rates BOM:524723 with a GF Score™ of 34/100 and a GF Value™ of ₹49.05 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Arvaya Healthcare's Research & Development for the three months ended in Mar. 2026 was ₹0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.00 Mil.

Arvaya Healthcare  (BOM:524723) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Arvaya Healthcare Research & Development Related Terms

Arvaya Healthcare Research & Development Historical Data

* Premium members only.

The historical data trend for Arvaya Healthcare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arvaya Healthcare Research & Development Chart

Arvaya Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arvaya Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:524723
34GF Score
Arvaya Healthcare Ltd BOM:524723
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arvaya Healthcare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.00 Mil mean?
Arvaya Healthcare (BOM:524723) has a Research & Development of ₹0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Arvaya Healthcare and its competitors.
Is Arvaya Healthcare's Research & Development too high?
Arvaya Healthcare's current Research & Development is ₹0.00 Mil. Overall, Arvaya Healthcare has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arvaya Healthcare's Research & Development compare to MCK and CAH?
Arvaya Healthcare's Research & Development of ₹0.00 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Arvaya Healthcare and its competitors. Arvaya Healthcare's current Research & Development is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arvaya Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Arvaya Healthcare (BOM:524723) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹49.05, compared to a current price of ₹67.11 — trading 36.8% above its estimated fair value. The current Research & Development is ₹0.00 Mil. Arvaya Healthcare's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Arvaya Healthcare (BOM:524723), the current Research & Development is ₹0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arvaya Healthcare (BOM:524723) Overvalued in 2026?

Based on GuruFocus' analysis, Arvaya Healthcare stock appears to be overvalued. The current stock price of ₹67.11 is trading 36.8% above its estimated GF Value™ of ₹49.05. GuruFocus considers Arvaya Healthcare to be Significantly Overvalued.

Key valuation signals for BOM:524723:

  • Research & Development: ₹0.00 Mil
  • GF Value™: ₹49.05 vs. price of ₹67.11 (36.8% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the BOM:524723 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arvaya Healthcare Business Description

Address G S Road, Nirvana Co Working spaces, Mezzanine Floor, Itag Plaza, ABC, Kamrup, Dispur, Gmc, Guwahati, AS, IND, 781005
Arvaya Healthcare Ltd is focused on developing an integrated healthcare platform in India that combines hospital services, diagnostics, wellness services, and digital health management solutions. Its operations include multi-specialty hospitals, a digital health platform for appointment booking and health record management, diagnostic services including laboratory testing and home sample collection, and wellness facilities offering preventive and recovery-focused programs.
34GF Score

Get the complete analysis for BOM:524723

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹67.11
Price
₹49.05
GF Value